Patent Leaderboard
USPTO Patent Rankings Data through Dec 31, 2025
Home › Use of APE1/Ref-1 inhibitors for treatment of retinal diseases

Use of APE1/Ref-1 inhibitors for treatment of retinal diseases

US Patent 12350247 · Granted Jul 8, 2025

Assignee

Inventors

View full patent text on Google Patents →

More Patents by These Inventors

Targeting ocular diseases with novel APE1/Ref-1 inhibitors2023
Use of APE1/Ref-1 inhibitors for treatment of retinal diseases2023
Use of APE1/Ref-1 inhibitors for treatment of retinal diseases2023
Prevention and reversal of inflammation induced DNA damage2022
Benzoquinone derivative E3330 in combination with chemotherapeutic agents for th2022
Compounds, compositions and methods for treating oxidative DNA damage disorders2021
Methods of targeting APE/Ref-1 to inhibit hypoxia signaling genes2020
Methods of targeting APE/Ref-1 to inhibit hypoxia signaling genes2020
Salicylic acid derivatives, pharmaceutically acceptable salt thereof, compositio2019
Quinone compounds for treating APE1 mediated diseases2018
Benzoquinone derivative E3330 in combination with chemotherapeutic agents for th2018
Quinone compounds for treating Ape1 mediated diseases2018